NEWS & RESEARCH

  • All
  • News Articles
  • Presentations
  • Press Release
  • Research Papers
Kurome Therapeutics

Kurome Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for KME-0584 for the Treatment of Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndromes (MDS)

February 15, 2024 Research Papers
Read More →
Kurome Therapeutics

Double trouble: IRAK1/4 inhibitors in AML/MDS

September 14, 2023 Research Papers
Read More →
Kurome Therapeutics

KUROME THERAPEUTICS TARGETS DYSREGULATED IMMUNE SIGNALING IN BLOOD CANCER PATIENTS

September 5, 2023 Press Release
Read More →
Kurome Therapeutics

Paralog-Specific Signaling By IRAK1/4 Maintains MyD88-Independent Functions In MDS/AML

May 12, 2023 Research Papers
Read More →
Kurome Therapeutics

Activation Of Targetable Inflammatory Immune Signaling Is Seen In Myelodysplastic Syndromes With SF3B1 Mutations

August 30, 2022 Research Papers
Read More →
Kurome Therapeutics

Innate Immune Pathways And Inflammation In Hematopoietic Aging, Clonal Hematopoiesis, And MDS

July 5, 2022 Research Papers
Read More →
Kurome Therapeutics

CCHMC Grand Rounds Presented By Jan Rosenbaum And Dan Starczynowski

February 15, 2022 Presentations
Read More →
Kurome Therapeutics

IRAK1 And IRAK4 As Emerging Therapeutic Targets In Hematologic Malignancies

January 1, 2022 Research Papers
Read More →
Kurome Therapeutics

Kurome Therapeutics: Rosenbaum’s Leadership Journey To Potentially Deliver Life-Saving Cancer Treatment

October 1, 2021 Press Release
Read More →
Kurome Therapeutics

Sequential CRISPR Gene Editing In Human IPSCs Charts The Clonal Evolution Of Myeloid Leukemia And Identifies Early Disease Targets

February 10, 2021 Research Papers
Read More →
Load More

Accessibility | Privacy | Terms

© 2023 Kurome® Therapeutics. All rights reserved.
Kurome is a registered trademark of Kurome Therapeutics. All rights reserved.